Ralle pilot: Response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 4, 2012, Pages 263-270

  Saarinen Pihkala, Ulla M ^a   Parto, Katriina ^b   Riikonen, Pekka ^c   Lähteenmäki, Päivi M ^d   Békàssy, Albert N ^e   Glomstein, Anders ^f   Möttönen, Merja ^g  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e University Hospital   (Sweden)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

acute lymphoblastic leukemia in children; ALL relapse; Minimal residual disease in ALL relapse; response to ALL chemotherapy; therapy for ALL relapse

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFANT; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; BONE MARROW; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDARUBICIN; INFANT; MALE; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; VINCRISTINE;

EID: 84860775046     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182352da9     Document Type: Article

References (26)

1. Gatta G, Corazziari I, Magnani C, et al. The EUROCARE working group. Childhood cancer survival in Europe. Ann Oncol. 2003;14(suppl 5):119-127.
2. Hijiya N, Gajjar A, Zhang Z, et al. Low-dose oral etoposidebased induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. Leukemia. 2004;18: 1581-1586. (Pubitemid 39386333)
3. Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukemia-lessons from the United Kingdom R2 trial. Br J Haemat. 2005;130:67-75. (Pubitemid 40979134)
4. Einsiedel HG, von Stackelberg A, Hartmann R, et al. Longterm outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lmphoblastic leukemiarelapse study of the Berlin-Frankfurt-Münster group 87. J Clin Oncol. 2005;23:7942-7950. (Pubitemid 46657394)
5. Rivera GK, Zhou Y, Hancock ML, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer. 2005;103:368-376. (Pubitemid 40129297)
6. Matsuzaki A, Nagatoshi Y, Inada H, et al. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation-A report from the Kyushu-Yamaguchi Children's Cancer Study Group. Pediatr Blood Cancer. 2005;45:111-120. (Pubitemid 40993575)
7. Saarinen-Pihkala UM, Heilmann C, Winiarski J, et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol. 2006;24:5750-5762. (Pubitemid 46631318)
8. Gaynon P, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and initial bone marrow relapse within 12 months of the completion of primary therapy: children's Oncology Group study CCG-1941. J Clin Oncol. 2006;24:3150-3156. (Pubitemid 46638953)
9. Paganin M, Zecca M, Fabbri G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed "high-risk" acute lymphoblastic leukemia. Leukemia. 2008;22:2193-2200.
10. Silverman LB. Acute lymphoblastic leukaemia. In: Orkin S, Fisher DE, Look AT, Lux SE, Ginsburg D, Nathan DG, eds. Oncology of Infancy and Childhood. Philadelphia: Saunders-Elsevier 2009 297-330.
11. Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapse or refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium study. J Clin Oncol. 2009;28:648-654.
12. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after timepoint and site-of-relapse stratification and intensified shortcourse multidrug chemotherapy: result of trial ALL-Rez BFM 90. J Clin Oncol. 2010;28:2339-2347.
13. Bader P, Kreyenberg H, Henze GHR, et al. Prognostic value of minimal residual disease quantification before allogeneic stemcell transplantation in relapsed childhood acute lymphoblastic leukaemia: the ALL-REZ BFM study group. J Clin Oncol. 2008;27:377-384.
14. Saarinen-Pihkala UM, Gustafsson G, Carlsen N, et al. Outcome of children with high-risk acute lymphoblastic leukemia: nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer. 2004; 42:8-23. (Pubitemid 38173452)
15. Gustafsson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukemia has improved prognosis, especially in non-high risk patients. The Nordic experience of 2648 patients diagnosed between 1981 and 1996. Acta Paediatr. 1998;87:1151-1161.
16. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia. 2000;14:2267-2275. (Pubitemid 32042267)
17. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24: 345-354.
18. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 2000;96:1709-1715. (Pubitemid 30661053)
19. Saarinen-Pihkala UM, Gustafsson G, Ringdén O, et al. No disadvantage in outcome in using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol. 2001;19:3406-3414. (Pubitemid 32642194)
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and experience. Br J Cancer. 1977; 35:1-39. (Pubitemid 8018922)
22. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2008;26:3971-3978.
23. Nguyen K, Devidas M, Cheung S-C, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008;22:2142-2150.
24. Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358:1239-1241. (Pubitemid 33010852)
25. Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol. 1986;12:231-249.
26. Mehta PA, Davies SM. Hematopoietic cell transplantation for acute lymphoblastic leukemia in children. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopietic Stem Cell Transplantation. 4th ed. New York: Blackwell Publishing; 2009:806-826.